Optipharm.CO.,LTD
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
153710 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청주시 흥덕구 오송읍 오송생명6로 63, 청주시
- Website:
- https://www.optipharm.co.kr
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Optipharm.CO.,LTD is a biotechnology company specializing in animal health and advanced biomedical solutions. The company's core activities include animal disease diagnosis, the development of veterinary pharmaceuticals, bacteriophage-based products, and Virus-Like Particle (VLP) vaccines. A key focus for Optipharm is xenotransplantation, where it conducts pioneering research and development of genetically engineered pigs for organ transplantation to address human organ shortages. The company has achieved significant milestones in preclinical trials, including record survival times for primates that have received transplanted organs, positioning it at the forefront of regenerative medicine and organ transplant technology.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Optipharm.CO.,LTD and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Optipharm.CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Optipharm.CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
